The Pitfalls of Disproportionality Analysis: Insights on Their Interwoven Complexity and a Front-End Mitigation Strategy
Drug Safety · 2026-12 · 49 (12) · 1541-1546
DOI: 10.1007/s40264-026-01707-0 ↗Kurz gefasst
Editorial in der Zeitschrift Drug Safety, online erschienen am 17.09.2026. Verfasst von Manfred Hauben und 2 weiteren Autor:innen. Beteiligte Einrichtung: Merck Healthcare KGaA, Frankfurter Straße 250, 64293, Darmstadt, Germany. manfred.hauben@emdserono.com. Die Arbeit nennt 12 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Merck Healthcare KGaA, Frankfurter Straße 250, 64293, Darmstadt, Germany. manfred.hauben@emdserono.com.
- Department of Family and Community Medicine, New York Medical College, 40 Sunshine Cottage Rd, Valhalla, NY, 10595, USA. manfred.hauben@emdserono.com.
- Oracle, 100 Oracle Pkwy, Redwood City, CA, 94065, USA.
Zitieren
APA
Hauben, M., Harpaz, R., & Weber, R. (2026). The Pitfalls of Disproportionality Analysis: Insights on Their Interwoven Complexity and a Front-End Mitigation Strategy. Drug Safety, 49(12), 1541-1546. https://doi.org/10.1007/s40264-026-01707-0
Vancouver
Hauben M, Harpaz R, Weber R. The Pitfalls of Disproportionality Analysis: Insights on Their Interwoven Complexity and a Front-End Mitigation Strategy. Drug Safety. 2026;49(12):1541-1546. doi:10.1007/s40264-026-01707-0
BibTeX
@article{Hauben2026,
author = {Hauben, Manfred and Harpaz, Rave and Weber, Robert},
title = {The Pitfalls of Disproportionality Analysis: Insights on Their Interwoven Complexity and a Front-End Mitigation Strategy},
journal = {Drug Safety},
year = {2026},
volume = {49},
number = {12},
pages = {1541--1546},
doi = {10.1007/s40264-026-01707-0}
}
EUVIMED